| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.467 | 0.042 | 0.511 | Calcium channel L-type activator | 0.511 0.024 CID_159040 | CID_159040 | |
| 0.386 | 0.007 | 0.386 | Anesthetic local | 0.267 0.017 CID_159040 | ||
| 0.322 | 0.018 | 0.322 | 5 Hydroxytryptamine 1E antagonist | 0.276 0.048 CID_159040 | ||
| 0.315 | 0.027 | 0.329 | Tyrosine 3 hydroxylase inhibitor | 0.329 0.022 CID_159040 | CID_159040 | |
| 0.218 | 0.009 | 0.218 | 5 Hydroxytryptamine 1F antagonist | 0.084 0.04 CID_159040 | ||
| 0.224 | 0.018 | 0.224 | Catenin beta inhibitor | 0.184 0.048 CID_159040 | ||
| 0.281 | 0.078 | 0.281 | Spasmolytic | 0.197 0.122 CID_159040 | ||
| 0.232 | 0.03 | 0.232 | Acetylcholine M1 receptor antagonist | 0.161 0.065 CID_159040 | ||
| 0.227 | 0.054 | 0.227 | Sigma receptor agonist | 0.119 0.116 CID_159040 | ||
| 0.331 | 0.162 | 0.332 | Caspase 9 stimulant | 0.332 0.161 CID_159040 | CID_159040 | |
| 0.17 | 0.012 | 0.17 | Acetylcholine nicotinic agonist | 0.169 0.012 CID_159040 | ||
| 0.192 | 0.034 | 0.192 | Cholinergic antagonist | 0.138 0.06 CID_159040 | ||
| 0.19 | 0.033 | 0.19 | Acetylcholine antagonist | 0.137 0.058 CID_159040 | ||
| 0.196 | 0.04 | 0.196 | ATPase inhibitor | |||
| 0.165 | 0.017 | 0.165 | Acetylcholine nicotinic antagonist | 0.137 0.024 CID_159040 | ||
| 0.293 | 0.147 | 0.293 | Analgesic | 0.243 0.189 CID_159040 | ||
| 0.241 | 0.105 | 0.334 | Insulysin inhibitor | 0.334 0.04 CID_159040 | CID_159040 | |
| 0.216 | 0.081 | 0.216 | Peptidyltransferase inhibitor | |||
| 0.143 | 0.009 | 0.143 | Nicotinic alpha4beta2 receptor antagonist | 0.134 0.012 CID_159040 | ||
| 0.298 | 0.167 | 0.399 | 5 Hydroxytryptamine release inhibitor | 0.399 0.078 CID_159040 | CID_159040 | |
| 0.247 | 0.122 | 0.247 | Interleukin 2 agonist | 0.247 0.122 CID_159040 | ||
| 0.13 | 0.008 | 0.13 | Nicotinic receptor alpha7 subunit antagonist | 0.086 0.015 CID_159040 | ||
| 0.131 | 0.015 | 0.131 | Neuronal nicotinic receptor antagonist | 0.108 0.021 CID_159040 | ||
| 0.233 | 0.122 | 0.233 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.195 0.163 CID_159040 | ||
| 0.137 | 0.028 | 0.17 | Nitric-oxide synthase inhibitor | 0.17 0.016 CID_159040 | CID_159040 | |
| 0.159 | 0.051 | 0.159 | Neurotrophic factor | 0.131 0.079 CID_159040 | ||
| 0.139 | 0.034 | 0.139 | Transcription factor STAT6 inhibitor | 0.122 0.056 CID_159040 | ||
| 0.144 | 0.039 | 0.144 | Falcipain 3 inhibitor | 0.098 0.073 CID_159040 | ||
| 0.22 | 0.118 | 0.22 | Gastrin inhibitor | 0.194 0.158 CID_159040 | ||
| 0.238 | 0.136 | 0.238 | Antithrombotic | 0.215 0.159 CID_159040 | ||
| 0.217 | 0.122 | 0.233 | 5 Hydroxytryptamine uptake stimulant | 0.233 0.1 CID_159040 | CID_159040 | |
| 0.113 | 0.018 | 0.113 | 5 Hydroxytryptamine 1D antagonist | |||
| 0.228 | 0.137 | 0.228 | Ca(v)3.3 blocker | |||
| 0.212 | 0.122 | 0.212 | Transcription factor STAT inhibitor | |||
| 0.114 | 0.025 | 0.114 | Bile acid receptor antagonist | 0.112 0.028 CID_159040 | ||
| 0.139 | 0.051 | 0.139 | Acetylcholine muscarinic antagonist | 0.098 0.093 CID_159040 | ||
| 0.12 | 0.036 | 0.12 | Opioid antagonist | 0.103 0.046 CID_159040 | ||
| 0.172 | 0.088 | 0.172 | P-glycoprotein inhibitor | 0.153 0.112 CID_159040 | ||
| 0.138 | 0.057 | 0.138 | Nav1.3 sodium channel blocker | |||
| 0.226 | 0.145 | 0.226 | Transcription factor NF kappa B inhibitor | 0.221 0.15 CID_159040 | ||
| 0.2 | 0.12 | 0.206 | Neuropeptide Y2 antagonist | 0.206 0.108 CID_159040 | CID_159040 | |
| 0.09 | 0.011 | 0.095 | Sphingosine kinase 2 inhibitor | 0.095 0.009 CID_159040 | CID_159040 | |
| 0.159 | 0.081 | 0.171 | Neurotensin receptor agonist | 0.171 0.061 CID_159040 | CID_159040 | |
| 0.163 | 0.088 | 0.163 | Amyloid beta precursor protein antagonist | |||
| 0.173 | 0.098 | 0.173 | Psychostimulant | |||
| 0.087 | 0.012 | 0.16 | Sphingosine kinase inhibitor | 0.16 0.004 CID_159040 | CID_159040 | |
| 0.113 | 0.039 | 0.113 | Acetylcholine agonist | 0.081 0.064 CID_159040 | ||
| 0.117 | 0.044 | 0.117 | Sphingomyelinase inhibitor | 0.103 0.057 CID_159040 | ||
| 0.136 | 0.063 | 0.138 | Sphingosine 1-phosphate receptor 2 antagonist | 0.138 0.059 CID_159040 | CID_159040 | |
| 0.083 | 0.012 | 0.083 | Nicotinic receptor alpha4 subunit antagonist | 0.053 0.028 CID_159040 | ||
| 0.136 | 0.067 | 0.136 | Nav1.2 sodium channel blocker | 0.106 0.102 CID_159040 | ||
| 0.153 | 0.085 | 0.153 | Growth hormone agonist | 0.153 0.085 CID_159040 | ||
| 0.111 | 0.045 | 0.111 | Prolactin inhibitor | 0.094 0.062 CID_159040 | ||
| 0.115 | 0.052 | 0.115 | Nav1.1 sodium channel blocker | |||
| 0.163 | 0.1 | 0.163 | Anesthetic general | |||
| 0.191 | 0.129 | 0.222 | Interleukin agonist | 0.222 0.101 CID_159040 | CID_159040 | |
| 0.098 | 0.037 | 0.098 | Opioid kappa receptor antagonist | 0.08 0.058 CID_159040 | ||
| 0.095 | 0.034 | 0.095 | Analgesic, opioid | 0.082 0.045 CID_159040 | ||
| 0.087 | 0.029 | 0.099 | MAP kinase kinase 7 inhibitor | 0.099 0.014 CID_159040 | CID_159040 | |
| 0.082 | 0.024 | 0.106 | NMDA 2C receptor antagonist | 0.106 0.014 CID_159040 | CID_159040 | |
| 0.091 | 0.035 | 0.091 | Opioid mu receptor antagonist | 0.068 0.047 CID_159040 | ||
| 0.195 | 0.14 | 0.195 | Transcription factor STAT3 inhibitor | |||
| 0.227 | 0.174 | 0.227 | Histamine release inhibitor | 0.21 0.19 CID_159040 | ||
| 0.095 | 0.042 | 0.175 | Inducible nitric-oxide synthase inhibitor | 0.175 0.011 CID_159040 | CID_159040 | |
| 0.063 | 0.011 | 0.063 | Nicotinic receptor beta4 subunit antagonist | |||
| 0.089 | 0.039 | 0.089 | CC chemokine 5 receptor agonist | 0.089 0.04 CID_159040 | ||
| 0.284 | 0.235 | 0.313 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.313 0.195 CID_159040 | CID_159040 | |
| 0.103 | 0.059 | 0.103 | Hedgehog signaling inhibitor | 0.099 0.067 CID_159040 | ||
| 0.079 | 0.037 | 0.079 | Potassium channel (Tandem pore domain) blocker | |||
| 0.083 | 0.042 | 0.133 | NMDA 2 receptor antagonist | 0.133 0.02 CID_159040 | CID_159040 | |
| 0.117 | 0.077 | 0.15 | Sphingosine 1-phosphate receptor 4 antagonist | 0.15 0.033 CID_159040 | CID_159040 | |
| 0.093 | 0.056 | 0.093 | Polo-like kinase-1 inhibitor | |||
| 0.132 | 0.096 | 0.152 | Sphingosine 1-phosphate receptor 5 antagonist | 0.152 0.058 CID_159040 | CID_159040 | |
| 0.071 | 0.036 | 0.071 | Acetylcholine M2 receptor antagonist | |||
| 0.074 | 0.039 | 0.074 | Protein kinase C beta inhibitor | |||
| 0.104 | 0.07 | 0.104 | Protein kinase C gamma inhibitor | |||
| 0.065 | 0.031 | 0.065 | Nicotinic neuronal receptor agonist | |||
| 0.058 | 0.024 | 0.058 | CXC chemokine 1 receptor antagonist | 0.052 0.034 CID_159040 | ||
| 0.055 | 0.022 | 0.055 | Nicotinic receptor alpha3 subunit antagonist | |||
| 0.131 | 0.099 | 0.158 | Anticoagulant | 0.158 0.074 CID_159040 | CID_159040 | |
| 0.21 | 0.179 | 0.219 | Calpain 2 inhibitor | 0.219 0.172 CID_159040 | CID_159040 | |
| 0.105 | 0.075 | 0.105 | Nav1.5 sodium channel blocker | |||
| 0.102 | 0.073 | 0.102 | 5 Hydroxytryptamine 3A agonist | |||
| 0.052 | 0.023 | 0.056 | Oxytocin agonist | 0.056 0.02 CID_159040 | CID_159040 | |
| 0.063 | 0.035 | 0.063 | Dopamine uptake inhibitor | 0.051 0.048 CID_159040 | ||
| 0.068 | 0.041 | 0.068 | Opioid delta receptor antagonist | 0.059 0.047 CID_159040 | ||
| 0.04 | 0.015 | 0.047 | Carnitine palmitoyltransferase 1 inhibitor | 0.047 0.009 CID_159040 | CID_159040 | |
| 0.172 | 0.147 | 0.222 | Nitric-oxide synthase stimulant | 0.222 0.057 CID_159040 | CID_159040 | |
| 0.063 | 0.039 | 0.063 | Prolactin release inhibitor | |||
| 0.062 | 0.039 | 0.062 | Acetylcholine M3 receptor antagonist | |||
| 0.174 | 0.15 | 0.274 | Superoxide dismutase inhibitor | 0.274 0.061 CID_159040 | CID_159040 | |
| 0.04 | 0.016 | 0.047 | Carnitine palmitoyltransferase inhibitor | 0.047 0.01 CID_159040 | CID_159040 | |
| 0.045 | 0.022 | 0.09 | Sphingosine kinase 1 inhibitor | 0.09 0.004 CID_159040 | CID_159040 | |
| 0.122 | 0.1 | 0.127 | Farnesoid X receptor antagonist | 0.127 0.089 CID_159040 | CID_159040 | |
| 0.061 | 0.04 | 0.061 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.059 0.046 CID_159040 | ||
| 0.045 | 0.026 | 0.071 | Histone deacetylase 8 inhibitor | 0.071 0.013 CID_159040 | CID_159040 | |
| 0.062 | 0.043 | 0.085 | Histone deacetylase SIRT3 inhibitor | 0.085 0.015 CID_159040 | CID_159040 | |
| 0.123 | 0.104 | 0.123 | Cholinergic | |||
| 0.07 | 0.053 | 0.07 | Polo-like kinase-2 inhibitor | |||
| 0.03 | 0.013 | 0.03 | 5 Hydroxytryptamine 1F agonist | |||
| 0.126 | 0.109 | 0.149 | Neuropeptide Y1 antagonist | 0.149 0.066 CID_159040 | CID_159040 | |
| 0.049 | 0.033 | 0.049 | Dopamine transporter inhibitor | 0.042 0.041 CID_159040 | ||
| 0.057 | 0.042 | 0.081 | Plasminogen activator inhibitor | 0.081 0.025 CID_159040 | CID_159040 | |
| 0.046 | 0.033 | 0.046 | Opioid mu receptor agonist | |||
| 0.092 | 0.08 | 0.092 | Estrogen receptor beta antagonist | |||
| 0.212 | 0.2 | 0.212 | 15-Lipoxygenase inhibitor | |||
| 0.103 | 0.092 | 0.103 | Estrogen antagonist | |||
| 0.079 | 0.07 | 0.079 | T cell inhibitor | |||
| 0.049 | 0.042 | 0.049 | Protein kinase C epsilon inhibitor | |||
| 0.132 | 0.126 | 0.132 | DNA methyltransferase I inhibitor | |||
| 0.13 | 0.123 | 0.13 | Heat shock protein 70 antagonist | |||
| 0.112 | 0.106 | 0.112 | Papain-like protease (SARS coronavirus) inhibitor | 0.111 0.11 CID_159040 | ||
| 0.12 | 0.115 | 0.149 | Hemostatic | 0.149 0.069 CID_159040 | CID_159040 | |
| 0.086 | 0.081 | 0.086 | Alpha 2d adrenoreceptor antagonist | |||
| 0.05 | 0.045 | 0.05 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.049 | 0.044 | 0.049 | Nicotinic alpha7 receptor agonist | |||
| 0.047 | 0.044 | 0.047 | Opioid agonist | |||
| 0.192 | 0.19 | 0.192 | Apoptosis antagonist | |||
| 0.038 | 0.037 | 0.038 | Opioid kappa receptor agonist | |||
| 0.056 | 0.055 | 0.056 | Dopamine D1 antagonist | |||
| 0.08 | 0.08 | 0.102 | Breast cancer-resistant protein inhibitor | 0.102 0.054 CID_159040 | CID_159040 | |
| 0.095 | 0.096 | 0.118 | Histone deacetylase class III inhibitor | 0.118 0.071 CID_159040 | CID_159040 | |
| 0.022 | 0.026 | 0.027 | Lysine carboxypeptidase inhibitor | 0.027 0.019 CID_159040 | CID_159040 | |
| 0.09 | 0.094 | 0.096 | Nav1.4 sodium channel blocker | 0.096 0.083 CID_159040 | CID_159040 | |
| 0.09 | 0.094 | 0.105 | Adenylate cyclase inhibitor | 0.105 0.08 CID_159040 | CID_159040 | |
| 0.045 | 0.052 | 0.051 | Factor III inhibitor | 0.051 0.032 CID_159040 | CID_159040 | |
| 0.068 | 0.083 | 0.142 | NMDA receptor antagonist | 0.142 0.027 CID_159040 | CID_159040 | |
| 0.033 | 0.049 | 0.049 | NMDA receptor subunit 3B antagonist | 0.049 0.026 CID_159040 | CID_159040 | |
| 0.112 | 0.132 | 0.12 | NOS3 expression enhancer | 0.12 0.114 CID_159040 | CID_159040 | |
| 0.025 | 0.045 | 0.049 | NMDA receptor subunit 3A antagonist | 0.049 0.02 CID_159040 | CID_159040 | |
| 0.02 | 0.042 | 0.029 | Endothelial nitric-oxide synthase inhibitor | 0.029 0.024 CID_159040 | CID_159040 | |
| 0.098 | 0.122 | 0.114 | Interleukin 4 antagonist | 0.114 0.094 CID_159040 | CID_159040 | |
| 0.012 | 0.039 | 0.024 | Integrin alphaVbeta1 antagonist | 0.024 0.009 CID_159040 | CID_159040 | |
| 0.03 | 0.06 | 0.081 | NMDA 2A receptor antagonist | 0.081 0.02 CID_159040 | CID_159040 | |
| 0.069 | 0.101 | 0.093 | Protease inhibitor | 0.093 0.072 CID_159040 | CID_159040 | |
| 0.057 | 0.09 | 0.069 | Somatostatin 1 agonist | 0.069 0.066 CID_159040 | CID_159040 | |
| 0.053 | 0.088 | 0.069 | Beta 2 adrenoreceptor agonist | 0.069 0.021 CID_159040 | CID_159040 | |
| 0.094 | 0.132 | 0.132 | Histone deacetylase SIRT1 inhibitor | 0.132 0.078 CID_159040 | CID_159040 | |
| 0.089 | 0.127 | 0.142 | Toll-Like receptor 2 antagonist | 0.142 0.059 CID_159040 | CID_159040 | |
| 0.023 | 0.062 | 0.039 | Histone deacetylase class I inhibitor | 0.039 0.027 CID_159040 | CID_159040 | |
| 0.029 | 0.074 | 0.078 | Dihydroorotase inhibitor | 0.078 0.009 CID_159040 | CID_159040 | |
| 0.056 | 0.102 | 0.126 | Adrenaline agonist | 0.126 0.023 CID_159040 | CID_159040 | |
| 0.017 | 0.064 | 0.11 | Somatostatin agonist | 0.11 0.007 CID_159040 | CID_159040 | |
| 0.026 | 0.078 | 0.047 | Melanocortin antagonist | 0.047 0.033 CID_159040 | CID_159040 | |
| 0.111 | 0.172 | 0.146 | CF transmembrane conductance regulator agonist | 0.146 0.084 CID_159040 | CID_159040 | |
| 0.006 | 0.069 | 0.06 | Somatostatin 2 agonist | 0.06 0.004 CID_159040 | CID_159040 | |
| 0.035 | 0.098 | 0.056 | Androgen agonist | 0.056 0.046 CID_159040 | CID_159040 | |
| 0.077 | 0.141 | 0.153 | Bone formation stimulant | 0.153 0.057 CID_159040 | CID_159040 | |
| 0.022 | 0.087 | 0.034 | Integrin alpha2 antagonist | 0.034 0.033 CID_159040 | CID_159040 | |
| 0.017 | 0.082 | 0.037 | Melanocortin 4 antagonist | 0.037 0.035 CID_159040 | CID_159040 | |
| 0.138 | 0.206 | 0.181 | 5 Hydroxytryptamine release stimulant | 0.181 0.139 CID_159040 | CID_159040 | |
| 0.04 | 0.108 | 0.061 | Histone deacetylase inhibitor | 0.061 0.051 CID_159040 | CID_159040 | |
| 0.034 | 0.107 | 0.056 | Sphingosine 1-phosphate receptor 3 antagonist | 0.056 0.045 CID_159040 | CID_159040 | |
| 0.12 | 0.194 | 0.14 | Death-associated protein kinase 2 inhibitor | 0.14 0.132 CID_159040 | CID_159040 | |
| 0.033 | 0.11 | 0.048 | Beta adrenoreceptor agonist | 0.048 0.021 CID_159040 | CID_159040 | |
| 0.129 | 0.209 | 0.162 | Calpain inhibitor | 0.162 0.161 CID_159040 | CID_159040 | |
| 0.018 | 0.107 | 0.039 | Dopamine D5 agonist | 0.039 0.029 CID_159040 | CID_159040 | |
| 0.024 | 0.122 | 0.053 | Beta 2 adrenoreceptor antagonist | 0.053 0.032 CID_159040 | CID_159040 | |
| 0.01 | 0.138 | 0.045 | Gonadotropin-releasing hormone receptor antagonist | 0.045 0.018 CID_159040 | CID_159040 | |
| 0.037 | 0.197 | 0.116 | Check point kinase 2 inhibitor | 0.116 0.052 CID_159040 | CID_159040 | |
| 0.018 | 0.189 | 0.07 | Phenylethanolamine N methyltransferase inhibitor | 0.07 0.005 CID_159040 | CID_159040 | |
| 0.027 | 0.208 | 0.058 | NMDA receptor agonist | 0.058 0.051 CID_159040 | CID_159040 | |
| 0.041 | 0.228 | 0.094 | GABA C receptor agonist | 0.094 0.074 CID_159040 | CID_159040 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |